A Phase 1 interventional study of Lu AF28996 in Healthy Participants, sponsored by H. Lundbeck A/S. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.
Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants.
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of Lu AF28996.
Drug: Lu AF28996
Oral solution containing radiolabelled \[14C\]-Lu AF28996.
Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces)
Time frame: From baseline (Day -1) up to 23 days post-dose
AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
AUC0-infinity of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Cmax of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Tmax of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
T½ of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Ran from Apr 2024 to primary completion in May 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lu AF28996